Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 LOW MAGNESIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 LOW MAGNESIUM IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration; electrolytes correct imbalances; low magnesium and calcium adjust levels in renal failure.
Intraperitoneal administration of dextrose and electrolytes creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane. Low magnesium formulation reduces magnesium load in patients with hypermagnesemia or renal impairment.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or 8-10 liters over 10-12 hours for overnight cycler, with dextrose concentration selected based on ultrafiltration needs.
Intraperitoneal instillation of 2 L (or as prescribed) of 2.5% dextrose-containing peritoneal dialysis solution, typically exchanged 4 times daily. The volume and frequency are individualized based on patient's size, residual renal function, and ultrafiltration needs.
None Documented
None Documented
Not applicable as a terminal half-life for the solution itself; glucose absorption half-life from peritoneal cavity is approximately 2-4 hours, reflecting peritoneal clearance. There is no systemic accumulation of the solution's components beyond expected glucose metabolism.
Not applicable; dextrose metabolism is rapid; dwell time in peritoneal cavity determines effect, typical 4-6 hours for dialysis.
Primarily eliminated via peritoneal drainage during continuous ambulatory peritoneal dialysis (CAPD). Approximately 60-80% of glucose is absorbed across the peritoneum and metabolized systemically; non-metabolized glucose and other solutes are removed in dialysate effluent. Renal excretion is negligible (<5%) in patients with end-stage renal disease on CAPD.
Peritoneal dialysis fluid components; dextrose is metabolized; electrolytes are absorbed/excreted via peritoneal route; no significant renal or biliary elimination.
Category C
Category C
Peritoneal dialysis solution
Peritoneal dialysis solution